The U.S. Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL®9, Merck’s 9-valent human papillomavirus (HPV) vaccine, to now include use in males 16 through 26 years of age. “This is an important approval that now aligns the indication for GARDASIL 9 in males and females ages 9 through 26 to that of GARDASIL, and also supports the CDC’s HPV vaccine recommendations for use in males,” said Jacques Cholat, M.D., president, Merck Vaccines.
Please see the full Merck press release for more information.